Three Years of Imatinib May Halve Death Rate in GIST Three Years of Imatinib May Halve Death Rate in GIST

Giving patients with high-risk gastrointestinal stromal tumors imatinib for 3 years rather than 1 year may reduce 10-year mortality by half, say German and Finnish investigators.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news